Clinical Trial Update: Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers [Phase 1]

View source ↗

Summary

Phase I trial of APL 400-003, an HIV vaccine candidate, conducted in HIV-negative volunteers; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• APL 400-003

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Acquired Immunodeficiency Syndrome, HIV Infection | Phase 1 | Status: COMPLETED